Brief: Cabaletta Bio Reports New Interim Data From The Descaartes™ Phase 1 Trial At The 31St EADV Congress
10/09/2022 12:04
Sept 10 (Reuters) - Cabaletta Bio Inc CABA.O :
* CABALETTA BIO PRESENTS NEW INTERIM DATA FROM THE
DESCAARTES™
PHASE 1 TRIAL AT THE 31ST EADV CONGRESS
* DOSES UP TO 7.5 BILLION DSG3-CAART CELLS (COHORT A5) WERE
GENERALLY WELL TOLERATED, WITH NO DLTS, AND ONE GRADE 1 CRS
* THERE WAS DOSE-DEPENDENT INCREASE IN DSG3-CAART
PERSISTENCE
THROUGH DAY 29 IN COHORTS A1 TO A4
Source text for Eikon: ID:nGNX5Wymlb
Further company coverage: CABA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsCabaletta Bio Q1 net loss widens as R&D costs rise
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity